Oritavancin (phosphate)
CAY-24091-5 5 mg
SDS: 
CAS
192564-14-0
Formulation
A crystalline solid
Purity
≥98%
MW
1989,1
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
Oritavancin is a semisynthetic glycopeptide antibiotic that inhibits the growth of Gram-positive bacteria.{39468} It inhibits transglycosylation and transpeptidation in the bacterial cell wall to disrupt membrane integrity.{39469,39470} Oritavancin inhibits the growth of clinical isolates from skin and soft-tissue infections, including methicillin-resistant and -susceptible S. aureus (MRSA, MSSA), vancomycin-resistant and -susceptible E. faecium (VREF, VSRF), as well as other staphylococci, streptococci, and enterococci (MIC90s = ≤0.008-0.5 mg/L).{39471} Oritavancin inhibits growth of S. aureus in a neutropenic-mouse thigh model of infection (ED50 = 0.95 mg/kg for a single dose).{39472} It improves survival in a mouse inhalation model of B. anthracis Ames anthrax when administered prophylactically pre- and postexposure and when administered post symptom development.{39473} Formulations containing oritavancin have been used to treat bacterial skin infections.
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
